LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $94.57.

Several research firms have recently commented on LMAT. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research boosted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price for the company.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $98.23 on Friday. The business’s fifty day moving average is $98.58 and its two-hundred day moving average is $91.67. The firm has a market cap of $2.21 billion, a P/E ratio of 53.68, a P/E/G ratio of 2.07 and a beta of 0.96. LeMaitre Vascular has a 52 week low of $56.04 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the prior year, the company earned $0.33 EPS. The firm’s quarterly revenue was up 15.6% on a year-over-year basis. On average, equities research analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were paid a $0.16 dividend. The ex-dividend date was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.65%. LeMaitre Vascular’s payout ratio is 34.97%.

Insider Transactions at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.79% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of LMAT. Annex Advisory Services LLC grew its holdings in shares of LeMaitre Vascular by 5.9% during the fourth quarter. Annex Advisory Services LLC now owns 31,677 shares of the medical instruments supplier’s stock worth $2,919,000 after buying an additional 1,769 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in LeMaitre Vascular by 11.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 19,942 shares of the medical instruments supplier’s stock valued at $1,837,000 after purchasing an additional 2,094 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in LeMaitre Vascular by 2.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 24,770 shares of the medical instruments supplier’s stock valued at $2,282,000 after buying an additional 677 shares during the last quarter. Franklin Resources Inc. lifted its position in LeMaitre Vascular by 5.2% during the 3rd quarter. Franklin Resources Inc. now owns 12,646 shares of the medical instruments supplier’s stock worth $1,165,000 after buying an additional 627 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth about $181,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.